The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage.

The nuclear exporter protein, Crm1, plays a key role in normal cell functioning, mediating the nucleo-cytoplasmic transport of cargo proteins. Elevated Crm1 expression has recently been identified in various tumours; however, the mechanisms driving its expression have not been investigated to date. In this study we identified the Crm1 promoter and factors associated with its elevated expression and with its repression under conditions of DNA damage. The -1405 to +99 Crm1 promoter region was found to be significantly more active in cancer and transformed cells compared to normal, and the -175 to +99 region identified as responsible for the differential activity. Mutation of two CCAAT boxes and a GC box within this region significantly diminished Crm1 promoter activity and ChIP analysis revealed binding of NFY and Sp1 to these sites, with increased binding in transformed and cancer cells. In addition, p53 was found to repress Crm1 promoter activity, after induction with doxorubicin, with p53 siRNA blocking the effect. Crm1 promoter constructs with mutated CCAAT boxes were significantly less responsive to p53 repression, and in vivo binding of NFY to the CCAAT boxes was diminished upon p53 binding, suggesting that p53 mediates repression of the Crm1 promoter via interfering with NFY. This was confirmed using NFY knock-down cells, in which Crm1 promoter activity was significantly less responsive to p53. In vitro EMSAs revealed that NFY and p53 bind the CCAAT boxes as a single complex under conditions of DNA damage. In summary, this study is a first to analyse Crm1 promoter regulation and reveals NFY and Sp1 as contributors to Crm1 overexpression in cancer. In addition, this study reveals that Crm1 transcription is inhibited by DNA damage and that the mechanism of inhibition involves p53 interfering with NFY function.

[1]  J. Black,et al.  Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.

[2]  D. Markovitz,et al.  YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter , 2002, Oncogene.

[3]  R. Mantovani,et al.  The molecular biology of the CCAAT-binding factor NF-Y. , 1999, Gene.

[4]  Q. Li,et al.  Effect of NF-κB Constitutive Activation on Proliferation and Apoptosis of Gastric Cancer Cell Lines , 2005, European Surgical Research.

[5]  B. Cullen,et al.  Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay , 1996, Molecular and cellular biology.

[6]  Chun Cheng,et al.  EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS , 2009, Neurosurgery.

[7]  Michael Q. Zhang,et al.  Integrative bioinformatics analysis of transcriptional regulatory programs in breast cancer cells , 2008, BMC Bioinformatics.

[8]  Fergus J Couch,et al.  p53 Mediates Repression of the BRCA2 Promoter and Down-regulation of BRCA2 mRNA and Protein Levels in Response to DNA Damage* , 2003, The Journal of Biological Chemistry.

[9]  Y. Dong,et al.  The expression of CRM1 is associated with prognosis in human osteosarcoma. , 2009, Oncology reports.

[10]  C. Johnston,et al.  Structure and promoter activity of the mouse CDC25A gene , 2000, Mammalian Genome.

[11]  J. Moore,et al.  Control of cyclin B1 localization through regulated binding of the nuclear export factor CRM1. , 1998, Genes & development.

[12]  D. Livingston,et al.  E2F4 Is Exported from the Nucleus in a CRM1-Dependent Manner , 2001, Molecular and Cellular Biology.

[13]  Tsung-Teh Wu,et al.  Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer , 2004, Clinical Cancer Research.

[14]  S. Roychoudhury,et al.  DNA damage induced p53 downregulates Cdc20 by direct binding to its promoter causing chromatin remodeling , 2009, Nucleic acids research.

[15]  Carsten Denkert,et al.  Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer , 2008, Cancer.

[16]  A. P. Butler,et al.  Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. , 1999, Cancer letters.

[17]  S. J. Thurston,et al.  SV40 stimulates expression of the transacting factor Sp1 at the mRNA level. , 1990, Genes & development.

[18]  L. Pemberton,et al.  Karyopherins: from nuclear-transport mediators to nuclear-function regulators. , 2004, Trends in cell biology.

[19]  W. Kim,et al.  NF-Y–Dependent Cyclin B2 Expression in Colorectal Adenocarcinoma , 2007, Clinical Cancer Research.

[20]  M. Birrer,et al.  The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation , 2009, International journal of cancer.

[21]  B. Bonavida,et al.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology , 2006, Oncogene.

[22]  R. Mantovani,et al.  Interactions between p300 and Multiple NF-Y Trimers Govern Cyclin B2 Promoter Function* , 2003, The Journal of Biological Chemistry.

[23]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[24]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[25]  H. Choy,et al.  p53 Negatively Regulates cdc2 Transcription via the CCAAT-binding NF-Y Transcription Factor* , 1999, The Journal of Biological Chemistry.

[26]  Patrick Fojas de Borja,et al.  Cyclin A–CDK phosphorylates Sp1 and enhances Sp1‐mediated transcription , 2001, The EMBO journal.

[27]  R. Sharan,et al.  Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. , 2003, Genome research.

[28]  Eugene Berezikov,et al.  CONREAL: conserved regulatory elements anchored alignment algorithm for identification of transcription factor binding sites by phylogenetic footprinting. , 2003, Genome research.

[29]  F. Chen,et al.  Ectopic expression of truncated Sp1 transcription factor prolongs the S phase and reduces the growth rate. , 2000, Anticancer research.

[30]  Li-wei Wang,et al.  Prognostic value of CRM1 in pancreas cancer. , 2009, Clinical and investigative medicine. Medecine clinique et experimentale.

[31]  T. Werner,et al.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. , 1995, Nucleic acids research.

[32]  B. Woda,et al.  Sp1, a New Biomarker That Identifies a Subset of Aggressive Pancreatic Ductal Adenocarcinoma , 2008, Cancer Epidemiology Biomarkers & Prevention.

[33]  Zhi-Liang Ji,et al.  Evolutionary and Transcriptional Analysis of Karyopherin β Superfamily Proteins *S , 2008, Molecular & Cellular Proteomics.

[34]  S. Maity,et al.  Stable Expression of a Dominant Negative Mutant of CCAAT Binding Factor/NF-Y in Mouse Fibroblast Cells Resulting in Retardation of Cell Growth and Inhibition of Transcription of Various Cellular Genes* , 2000, The Journal of Biological Chemistry.

[35]  R. Mantovani,et al.  Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters , 2005, Molecular and Cellular Biology.

[36]  Giulia Piaggio,et al.  Posttranslational regulation of NF-YA modulates NF-Y transcriptional activity. , 2008, Molecular biology of the cell.

[37]  S. Benchimol,et al.  Transcriptional repression mediated by the p53 tumour suppressor , 2003, Cell Death and Differentiation.

[38]  Jonathan M. Lee,et al.  p53 is a NF‐Y‐ and p21‐independent, Sp1‐dependent repressor of cyclin B1 transcription , 2005, FEBS letters.

[39]  Giulia Piaggio,et al.  The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated , 1999, Oncogene.

[40]  M. Yanagida,et al.  Molecular Cloning and Cell Cycle-dependent Expression of Mammalian CRM1, a Protein Involved in Nuclear Export of Proteins* , 1997, The Journal of Biological Chemistry.

[41]  D. Lane,et al.  Activation of p53 in cervical carcinoma cells by small molecules. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Mantovani,et al.  A survey of 178 NF-Y binding CCAAT boxes. , 1998, Nucleic acids research.

[43]  G. Firestone,et al.  Indole-3-carbinol Inhibits CDK6 Expression in Human MCF-7 Breast Cancer Cells by Disrupting Sp1 Transcription Factor Interactions with a Composite Element in the CDK6 Gene Promoter* , 2001, The Journal of Biological Chemistry.

[44]  B. Nelson,et al.  Stat5 and Sp1 Regulate Transcription of the Cyclin D2 Gene in Response to IL-21 , 2001, The Journal of Immunology.

[45]  E. O’Shea,et al.  Nuclear transport and transcription. , 2000, Current opinion in cell biology.

[46]  T. Karpova,et al.  Crm1 is a mitotic effector of Ran-GTP in somatic cells , 2005, Nature Cell Biology.

[47]  Chiara Vecchi,et al.  Dynamic Recruitment of NF-Y and Histone Acetyltransferases on Cell-cycle Promoters* , 2003, Journal of Biological Chemistry.

[48]  Carol S. Lim,et al.  Controlling Protein Compartmentalization to Overcome Disease , 2006, Pharmaceutical Research.

[49]  Minoru Yoshida,et al.  CRM1 is responsible for intracellular transport mediated by the nuclear export signal , 1997, Nature.

[50]  I. Eto.  Molecular cloning and sequence analysis of the promoter region of mouse cyclin D1 gene: implication in phorbol ester‐induced tumour promotion , 2000, Cell proliferation.

[51]  M. Abdelrahim,et al.  Sp transcription factor family and its role in cancer. , 2005, European journal of cancer.

[52]  S. Pradhan,et al.  Molecular Mechanisms of Transactivation and Doxorubicin-mediated Repression of survivin Gene in Cancer Cells* , 2007, Journal of Biological Chemistry.

[53]  C. Dargemont,et al.  Evidence for a role of CRM1 in signal-mediated nuclear protein export. , 1997, Science.

[54]  S. Mutka,et al.  Identification of nuclear export inhibitors with potent anticancer activity in vivo. , 2009, Cancer research.

[55]  Kuang Yu Chen,et al.  The age-dependent binding of CBP/tk, a ccaat binding protein, is deregulated in transformed and immortalized mammalian cells but absent in premature aging cells , 1996, Experimental Gerontology.

[56]  S. N. Agoff,et al.  Regulation of the human hsp70 promoter by p53. , 1993, Science.